Pharmaceutical Executive-02-01-2019

Pharmaceutical Executive

Q&A: Regulatory Reform in China

February 19, 2019

Features

39

2

Dr. Lingshi Tan, a director at DIA, and chairman and CEO of Shanghai-based CRO dMed Company Limited, which he founded after establishing R&D operations for Pfizer in China, discusses the nation's regulatory evolution and opportunities for its government to strengthen collaborations with FDA and other leading global agencies.

A Leading Man’s Next Act

February 08, 2019

Features

39

2

Pharm Exec profiles Dr. Xiaobin Wu, an accomplished leader in helming China operations at big pharmas such as Pfizer and Bayer, who believes his recent jump to biotech as GM of China and president of BeiGene will deliver his most lasting legacy.

Two Steps Forward

February 08, 2019

From the Editor

39

2

Green-lighting China as our coverage focus in the February issue wasn't without conflict or hesitation, but as our reporting of the nation's biopharma landscape shows, perseverance and growth many times go hand-in-hand.

Let the Drug Pricing Games Begin

February 07, 2019

Columns

39

2

Drug importing, advertising, rebates, and industry practices are on the table as legislators zero in on pharma pricing strategies.

CFIUS Reform’s Impact on Biopharma

February 06, 2019

Features

39

2

What the new rules mean for Chinese-related investments and acquisitions in the US.

Pharmaceutical Executive, February 2019 Issue (PDF)

February 01, 2019

Issue PDF

39

2

Click the title above to open the Pharmaceutical Executive February 2019 issue in an interactive PDF format.

Country Report: Spain

February 01, 2019

Special Sponsored Section

39

2

With Spain now squarely on the road to economic recovery following the ravages of the global financial crisis, multinational pharmaceutical companies are seeing the country as a top-tier investment destination once more.